Golexanolone, also known by the developmental code name GR-3027, is a neurosteroid medication which is under development for the treatment of hypersomnia and hepatic encephalopathy.[1][2][3][4] It acts as a negative allosteric modulator of the GABAA receptor.[1][2] The medication selectively antagonizes the stimulatory actions of inhibitory neurosteroids like allopregnanolone and tetrahydrodeoxycorticosterone (THDOC) at the GABAA receptor, while not affecting the activation of the GABAA receptor by γ-aminobutyric acid (GABA).[2]
Clinical data | |
---|---|
Other names | GR-3027; 3α-Ethynyl-3β-hydroxyandrostan-17E-one oxime |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C21H31NO2 |
Molar mass | 329.484 g·mol−1 |
3D model (JSmol) |
|
| |
|